Novelix Pharmaceuticals share price
BSE: 536565Healthcare ServicesSmall Cap
Last close ₹59.54down ₹3.19 (5.09%)
Share price at the BSE close on 23 Oct 2026. Previous close ₹62.73.
52-week range of traded prices to 23 Oct 2026
₹45.03Low, 23 Oct 2025₹92.00High, 16 Jun 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹170 Cr2,861st largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 13 Aug 2026
- 46.7
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet.
- Shares changed
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 13 Aug 2026
- 11.3%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 13 Aug 2026
- 8.7%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 29 May 2026
- 0.09
- Volume, BSEVolume. Shares traded on the last trading day.
- 1,524
Results
Standalone, as consolidated accounts are on record for only 5 of the last ten years; ₹ crore, the charts by years to March, the table by quarter. No standalone results on record for the years to Mar 2022 and Mar 2024.Quarterly results
Quarter to Jun 2026, against the quarter beforeFiled 13 Aug
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹37 Crup 46.52%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹1.18 Crup 29.28%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax.
- 3.2%
Revenue by year
Peak revenue ₹132 Cr, year to Mar 2026
Net profit by year, a loss in red
- Net profit
- Loss
A loss in 2 of the 8 years with results on record
| ₹ crore | Sep 2024Filed 15 Nov | Dec 2024Filed 13 Feb | Mar 2025Filed 12 Jun | Jun 2025Filed 14 Aug | Sep 2025Filed 13 Nov | Dec 2025Filed 12 Feb | Mar 2026Filed 29 May | Jun 2026Filed 13 Aug |
|---|---|---|---|---|---|---|---|---|
| Revenue | 4.0 | 5.3 | 20.9 | 22.4 | 36.4 | 48.4 | 25.2 | 36.9 |
| Net profit | 0.1 | 0.1 | 0.2 | 0.1 | 0.5 | 1.0 | 0.9 | 1.2 |
| Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. | 3.3% | 2.8% | 0.9% | 0.5% | 1.5% | 2.1% | 3.6% | 3.2% |
Standalone. The last eight quarters. The latest is shaded.
Business segments
One segment, Pharma Business, carries all the revenue in the year to Mar 2026.
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | +109.6% | +1,327.8% | −85.3% | 0.0% |
| 3 years | +83.7% | – | – | 0.0% |
| 5 years | +52.5% | – | – | 0.0% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add. Earnings growth and the change in P/E are left empty where earnings per share at either end of the window was a loss or is not on record. Earnings growth over 1 and 3 years is on profit divided by shares in issue at both ends: the earnings per share stated for one end does not match that year's profit and share count.
Peers and competitors
Healthcare Research, Analytics & Technology, 11 listed companies, priced on 23 Oct 2026. The table lists the 8 companies closest to Novelix Pharmaceuticals in market cap.
Where the company sits among the companies nearest its size
| Company | |||||||||
|---|---|---|---|---|---|---|---|---|---|
 IndegeneINDGN | 13,781 | 34.4 | 4.4 | 21.0 | +30.4% | −7.9% | 13.9% | 15.6% | 0.39% |
 Suven Life SciencesSUVEN | 7,385 | – | – | – | +17.3% | – | −100.5% | −63.0% | 0.00% |
 Vimta LabsVIMTALABS | 2,092 | 26.3 | 4.6 | 14.0 | +15.2% | – | 19.1% | 21.4% | 0.43% |
 BilcareBI | 197 | – | 1.0 | 11.5 | −0.9% | – | – | 5.4% | 0.00% |
 Jeevan Scientific TechnologyJSTL | 163 | – | 2.3 | 11.7 | +66.1% | – | – | 8.8% | 0.00% |
 TAKETAKE | 162 | 12.6 | 5.2 | – | – | −68.2% | 49.8% | −5.6% | 0.00% |
 GlobalSpace Technologies540654 | 82 | – | 1.4 | 12.0 | +37.2% | – | – | 7.5% | 0.00% |
 Adeshwar MeditexADESHWAR | 27 | 21.4 | 0.7 | – | – | – | 3.4% | – | 0.00% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Latest announcements
Routine notices left out.Share news and announcements
Oct 2026
2 Oct · Management
1 Oct · Results
Sep 2026
7 Sep · Meeting
7 Sep · Meeting
Novelix Pharmaceuticals share price by year
Each calendar year to 2025.Novelix Pharmaceuticals share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 62.62 | +159.3% | 66.82 | 24.15 |
| 2024 | 24.15 | +114.7% | 24.15 | 8.10 |
| 2023 | 11.25 | +8.7% | 11.96 | 8.00 |
| 2022 | 10.35 | +54.5% | 10.45 | 7.00 |
| 2021 | 6.70 | +8.4% | 10.62 | 4.28 |
| 2020 | 6.18 | +123.1% | 7.09 | 1.85 |
| 2019 | 2.77 | −60.4% | 7.00 | 2.77 |
| 2018 | 7.00 | −22.2% | 9.56 | 6.89 |
| 2017 | 9.00 | +36.4% | 9.87 | 5.70 |
| 2016 | 6.60 | −14.3% | 9.25 | 5.61 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before. 2020 is from its first session, 17 Jan 2020. 2019 is from its first session, 10 May 2019. The 2018 close is its last trade, on 12 Sep 2018.
Recent sessions
The last 10 trading days to 23 Oct 2026, as traded on BSE.
| Date | Open | High | Low | Close | Average price | Volume |
|---|---|---|---|---|---|---|
| 23 Oct 2026 | 59.00 | 62.00 | 59.00 | 59.54 | 59.95 | 1,524 |
| 22 Oct 2026 | 60.10 | 62.74 | 60.10 | 62.73 | 62.03 | 1,364 |
| 21 Oct 2026 | 63.98 | 64.00 | 61.01 | 62.74 | 62.62 | 373 |
| 19 Oct 2026 | 63.41 | 64.72 | 57.40 | 64.13 | 63.01 | 1,618 |
| 16 Oct 2026 | 65.85 | 65.85 | 62.20 | 63.41 | 63.41 | 3,858 |
| 15 Oct 2026 | 67.95 | 67.95 | 63.00 | 63.89 | 64.04 | 4,005 |
| 14 Oct 2026 | 69.20 | 69.29 | 62.25 | 65.44 | 64.24 | 5,109 |
| 13 Oct 2026 | 71.88 | 72.00 | 61.50 | 64.08 | 65.00 | 3,245 |
| 12 Oct 2026 | 69.20 | 69.30 | 64.40 | 64.47 | 65.51 | 2,247 |
| 9 Oct 2026 | 69.00 | 71.90 | 66.00 | 68.48 | 68.66 | 1,890 |
Prices in ₹ per share as traded, not adjusted.
Company details
- Legal name
- NOVELIX PHARMACEUTICALS LIMITED
- BSE code
- 536565
- ISIN
- INE314I01036
- Industry
- Healthcare Services
- Listed
- Oct 2013
- Face value
- ₹10
- CIN
- L67120TG1994PLC018956
- Corporate identity number, the registrar of companies' code for it